Triple-Neg Breast Cancer

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells.
Baquero JM, Marchena-Perea E, Mirabet R, Torres-Ruiz R, Blanco-Aparicio C, Rodríguez-Perales S, Helleday T, Benítez-Buelga C, Benítez J, Osorio A.
Front Oncol. 2022 May 10;12:888810. doi: 10.3389/fonc.2022.888810.

Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
Chavarri-Guerra Y, Villarreal-Garza C, Ferrigno AS, Mohar A, Aguilar D, Alvarez-Gomez RM, Gallardo-Alvarado L, Del Toro-Valero A, Quintero-Beulo G, Gutierrez-Delgado F, Rodriguez-Olivares JL, Ochoa-Chavez MF, Gutierrez-Seymour G, Castillo D, Herzog J, Weitzel JN.
Salud Publica Mex. 2022 Feb 25;64(1):41-48. doi: 10.21149/12704.

Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily.
Stella S, Vitale SR, Martorana F, Massimino M, Pavone G, Lanzafame K, Bianca S, Barone C, Gorgone C, Fichera M, Manzella L.
Cancer Manag Res. 2022 Apr 5;14:1341-1352. doi: 10.2147/CMAR.S348529.

LitAlert ~~ GeneLit.com

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E.
NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1.

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.
de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
J Clin Oncol. 2022 Mar 30:JCO2101536. doi: 10.1200/JCO.21.01536. Epub ahead of print.

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs.
Sklias T, Vardas V, Pantazaka E, Christopoulou A, Georgoulias V, Kotsakis A, Vasilopoulos Y, Kallergi G.
Cancers (Basel). 2022 Mar 29;14(7):1731. doi: 10.3390/cancers14071731.

Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
Breast. 2022 Mar 19:S0960-9776(22)00065-0. doi: 10.1016/j.breast.2022.03.011. Epub ahead of print.

Post-Neoadjuvant Treatment Strategies in Breast Cancer.
Matuschek C, Jazmati D, Bölke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckhäberle E, Fehm T, Nestle Krämling C, Dommach M, Haussmann J.
Cancers (Basel). 2022 Feb 28;14(5):1246. doi: 10.3390/cancers14051246.

A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021.
Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z.
Cancers (Basel). 2022 Feb 28;14(5):1253. doi: 10.3390/cancers14051253.

Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.
Miglietta F, Bottosso M, Griguolo G, Dieci MV, Guarneri V.
ESMO Open. 2022 Feb 25;7(2):100409. doi: 10.1016/j.esmoop.2022.100409. Epub ahead of print.